Associated Papers
Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemia.
Newman H et al.
Hemasphere, 2025
An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia.
Torres-Diz M et al.
Cancer Research, 2024
An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia.
Torres-Diz M et al.
Biorxiv : the Preprint Server for Biology, 2024
CRISPR/Cas9-Mediated Induction of Relapse-Specific NT5C2 and PRPS1 Mutations Confers Thiopurine Resistance as a Relapsed Lymphoid Leukemia Model.
Nguyen TTT et al.
Molecular Pharmacology, 2023
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution.
Richter-Pechańska P et al.
Leukemia, 2022
NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
Somazu S et al.
Journal of Cellular and Molecular Medicine, 2021
Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
Barz MJ et al.
Blood, 2020
Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures.
Billon P et al.
Cell Reports, 2020
Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia.
Moriyama T et al.
Molecular Cancer Therapeutics, 2019
NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia.
Kimura S et al.
Cancer Science, 2019
Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Dieck CL et al.
Cancer Cell, 2018
Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
Hnízda A et al.
Leukemia, 2018
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Tzoneva G et al.
Nature, 2018
Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.
Richter-Pechańska P et al.
Blood Cancer Journal, 2017
Oligomeric interface modulation causes misregulation of purine 5´-nucleotidase in relapsed leukemia.
Hnízda A et al.
Bmc Biology, 2016
Leukemia Relapse-Associated Mutation of NT5C2 Gene is Rare in de Novo Acute Leukemias and Solid Tumors.
Oh HR et al.
Pathology Oncology Research : Por, 2016
Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
Li B et al.
Nature Medicine, 2015
Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
Ma X et al.
Nature Communications, 2015
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Meyer JA et al.
Nature Genetics, 2013
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G et al.
Nature Medicine, 2013
Therapeutic resistance: ALL-important mutations.
Seton-Rogers S
Nature Reviews. Cancer, 2013